The drug named MTL-CEBPA is now entering Phase 2 clinical trials for patient with advanced hepatocellular carcinoma (HCC) and has been shown to be safe, with no maximum dose reached in the first-dose escalation study [125,126]. The gene discussed is CEBPA; the disease is hepatocellular carcinoma.